Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, and Chronic Myeloid Leukemia Treatments.
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia
SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in <i>FLT3</i> -mutated AML
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML.
Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations.
Risk Stratification in Older Intensively Treated Patients With AML.
SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia.
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapy
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AML
Optimal Post-Remission Consolidation Therapy in Patients with AML
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Unified classification and risk-stratification in Acute Myeloid Leukemia
Pretransplant <i>FLT3</i>-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
Overlapping features of therapy-related and de novo <i>NPM1</i>-mutated AML
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
Therapy for isocitrate dehydrogenase 2 (IDH2)<sup>R172</sup> -mutant acute myeloid leukaemia.
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.